Obe­si­ty drug race heats up as In­novent un­corks new GLP1 da­ta

While Eli Lil­ly has been hy­per-fo­cused on de­thron­ing No­vo Nordisk’s semaglu­tide in the di­a­betes and obe­si­ty space, an­oth­er chal­lenger sneaked up from be­hind.

In­novent Bi­o­log­ics burst on­to the scene Tues­day with Phase II da­ta show­ing its GLP-1 re­cep­tor/glucagon re­cep­tor dual ag­o­nist re­duced pa­tients’ body weights by more than 12% at the high­est dose com­pared to place­bo.

The obe­si­ty study en­rolled 248 Chi­nese par­tic­i­pants with 230 com­plet­ing a full 24 weeks of treat­ment on ei­ther vary­ing dos­es of once-week­ly maz­du­tide in­jec­tions or place­bo. At the high­est 6-mg dose, maz­du­tide pa­tients saw an 11.57% re­duc­tion in body weight from base­line, com­pared to the 1.05% re­duc­tion seen by place­bo pa­tients (p < 0.0001). That com­pares to a 7.21% re­duc­tion from base­line on the low­est dose, 3 mg.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.